The role of BRAF mutations in primary melanoma growth rate and survival.

摘要: Summary Background The clinical behaviour and prognosis of primary melanomas harbouring BRAF mutations is not fully understood. Objectives To investigate the effect mutation status on melanoma growth rate melanoma-specific survival (MSS). Methods A prospective cohort 196 patients with stage I–III cutaneous were followed for a median 92 months, pre-dating institution inhibitor therapy. Clinicopathological variables correlated hazard ratios (HRs) estimated MSS. Results Of tumours, 77 (39·2%) V600E, 10 (5·1%) V600K 33 (16·8%) NRAS mutant. V600E mutant associated favourable characteristics tended to be slower growing compared V600K, or BRAF/NRAS wild-type tumours (0·12 mm per month, 0·61 mm 0·36 mm month 0·23 mm respectively; P = 0·05). There 39 deaths, poorer MSS in disease [HR 2·60, 95% confidence interval (CI) 1·20–5·63; P = 0·02] I–II (HR 3·39, CI 1·12–10·22; P = 0·03) after adjusting other prognostic variables. Considered separately, strongly independently thickness nodal 3·89, 1·67–9·09; P < 0·01) but 1·19, 0·36–3·92; P = 0·77). Conclusions The presence does necessarily ‘drive’ more rapid tumour early-stage disease.